Weekly injections for stomach side effects in overweight people
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests two weekly hormone injections (GIP and amylin) to see how they affect stomach-related side effects in people who are overweight or obese. Researchers want to understand if these hormones can help manage weight or related symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were assigned female at birth.
- You are between 18 and 64 years old.
- Your body mass index (BMI) is between 27 and 39.9.
- Your excess weight is mostly from body fat (as judged by a doctor).
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective birth control if you could become pregnant.
- You have not taken weight-loss drugs or had certain weight-loss surgeries in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
This trial tests an experimental medication that may help with weight loss. It aims to see how safe the drug is and how the body responds, possibly leading to a new treatment option for obesity.
This study tests a new injectable medication (SYH2082) that works like GLP-1 and GIP drugs to see how safe it is and how your body handles it. You must be healthy with no diabetes, thyroid cancer risk, or recent major surgery.
This study tests an experimental once-weekly injection called ribupatide for people with type 2 diabetes and overweight. It aims to help them lose weight and better control their blood sugar.
This trial tests a new injection (BGM1812) for weight loss in people who are overweight or obese. The injection is given under the skin, and the study will see how it works in your body and how safe it is.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.